A small trial of fingolimod was initiated with the aim of assessing whether sequestration of lymphocytes via S1PR1 antagonism could reduce post-chemoradiation lymphopenia in glioblastoma patients, but results have not yet been published (NCT02490930). Here, S1PR1 is linked to glioblastoma.